Apart from the GRPR- and PSMA- or GRPR- and integrin αvβ3-bispecific heterobivalent agents developed for PCa imaging or therapy, other strategies were followed to improve the targeting of this malignancy using peptide heterodimers. The gene discussed is FOLH1; the disease is posterior cortical atrophy.